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Finding Genetic Regulators, Forecasting Function
The advent of whole-genome sequencing promised, among other things, that variants affecting regulatory regions of the genome could be identified to provide insight into inherited pathologies or the impact of de novo mutations. These gains are accruing but still lag expectations. While whole-genome sequences accumulate in both academic and clinical settings, one inescapable limitation is that identifying functional regulatory sequences-be they enhancers, promoters, UTRs-that control specific genes remains difficult at the level of basic research. There is a growing understanding of how sequence elements contribute to genome organization and gene regulation (Hnisz et al., 2016) . However, no experimental or computation approach can, as yet, consistently and reliably predict or identify the cis-regulatory elements that exert transcriptional control over a gene of interest. The challenge in human genetics is then 2-fold: amass the numbers of individual sequences required to be able to confidently identify candidate cis-regulatory variants (as distinct from noise) and then find some way to prioritize those sequences in a functional context.
Phylogenetic comparisons between organisms can be helpful in breaking this log-jam. However, in some cases for human genetics, the important sequences are those that are uniquely human. Yet this kind of comparison between human sequences and those from great apes has been hampered by variability in the reference sequences of the latter. Limitations due to uneven sequence coverage and quality has been exacerbated by the use of human sequences to aid in genome alignments and gene calling. In effect, elements of the great ape sequences might look more human than they should because of a technical bias. Aiming to address this issue, recent work from Evan Eichler's group (Kronenberg et al., 2018) reports new sequences and assemblies of chimpanzee and orangutan genomes without use of a human framework. This study, in concert with their earlier work on the gorilla genome (Gordon et al., 2016) , enables researchers to look at key differences among these primates. The authors leveraged long-read sequencing of iPSCs to develop new gene models and cerebral organoids as a surrogate to look more closely at chimp-human comparisons during brain development. They find that structural variations (SVs) affect putative regulatory regions, including superenhancers, and are more likely to affect gene expression than expected. The RNAs produced reflect these differences as, for example, humans and chimps show significant differences in key neuronal cell types that track with human-specific SVs. These newly identified human-specific variants are an invitation to the broader community to tackle how they function and whether they are tied to pathologies or uniquely human biology.
How variants affecting regulatory sequences contribute to disease phenotypes is a long-standing question. In different disease contexts, progress has been slowed by a lack of sufficient sequence numbers to confidently pull rare variants out of the background noise. Single-nucleotide variants pose the greatest challenge, but structural variants are becoming accessible. New work from Jonathan Sebat and colleagues (Brandler et al., 2018) focuses on identifying cis-regulatory structural variants in a large-scale autism cohort. Their approach to assessing regulatory elements that might be significant for the disorder relies on constraints derived from patterns in the general population. Previous work characterized genes for their tolerance or intolerance to loss-of-function (LOF) mutations (Samocha et al., 2014) and found that autism cases tend to carry coding mutations in the top 1,000 genes that are intolerant to loss-of-function mutation in a general population from the Exome Aggregation Consortium (ExAC). Using this as a point of comparison, sequences that show negative selection for SVs in the general population but harbor SVs in individuals in the new cohort can be prioritized. In examining the sequences, the authors subdivided regions into ''cis regulatory'' and ''coding and noncoding,'' which could then be overlaid with information about intolerance to LOF. Unexpectedly, they report selective transmission of paternal cis regulatory (CRE) SVs in intolerant genes. As earlier studies pointed to maternal contributions to inherited variants, the notion that inherited CRE structural variants have a distinct paternal bias necessitates new models for thinking about autism spectrum disorder.
One way to get a leg up on understanding how SVs in regulatory sequences affect functional gene expression is start with a known pool of regulatory sequences. Matthew Hurles and his colleagues took this approach when looking at individuals with undiagnosed neurodevelopmental disorders (Short et al., 2018) . Over 50% of the individuals in the Deciphering Developmental Disorders study lack classifiable variants in a protein-coding gene. To look for contributing cis-regulatory sequences, the study focuses on evolutionarily conserved non-coding elements (CNEs), experimentally validated enhancers, and putative heart-specific enhancers as cardiovascular disease was the most frequent non-neurological clinical phenotype detected in individuals. De novo mutations in CNEs were correlated with DNase hypersensitivity sites across tissues to identify candidates with a higher likelihood of being functional. These show a degree of enrichment for de novo mutations, whereas validated enhancers did not, suggesting that these sequences could be plumbed for distinct regulatory contributions. The study then focused on analysis of expression in fetal brain where there was a strong enrichment of de novo mutations. Although the mutations were broadly associated with genes linked to early prenatal brain development rather than developmental disorders by Hi-C, there was no basis to causally link to specific regulatory variants. Interestingly, the study reports some incidence of recurrent mutation of certain CNEs and conserved enhancers, providing a rationale for further exploration of these sequences.
These three studies make significant steps in both identifying candidate regulatory regions and prioritizing structural variants in regulatory sequences. Both kinds of information are necessary to understand whether variants in cis-regulatory elements contribute broadly to human genetic disease. Both the neurodevelopment and autism studies provide some insight on this score. For the neurodevelopment cohort, the effect size seems quite modest with 0.15% of the variants forecast as penetrant and potentially pathological. Similarly, inherited cis-regulatory SVs are modeled in 0.77% of cases in the autism study. In each case, these values fall below what is observed for coding variants, calling into question the significance of their contributions. However, gauging the functional significance of these variants will ultimately require multiple technologies to marry sequencing information and linkage of regulatory sequences to specific genes. What may seem to be a minor-league player based on stats, may turn out to be a major-league contributor when put on the field-for humans, the suite of variants, both inherited and de novo, that make each individual truly individual.
